Neuphoria Therapeutics (NEUP) Share-based Compensation (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Share-based Compensation of $100000.0 for Q1 2026, little changed year-over-year from $100000.0 in Q1 2025, and little changed on a QoQ basis from $100000.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Share-based Compensation data on file, last reported at $100000.0 in Q1 2026.
- Quarterly Share-based Compensation changed 0.0% year-over-year to $100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $445772.0 (up 39.46% YoY) and the FY2025 annual result came in at $200000.0, down 75.0% from the prior year.
- Share-based Compensation was little changed at $100000.0 in Q1 2026 per NEUP's latest filing, from $100000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $700000.0 in Q4 2023 and bottomed at $26736.0 in Q3 2024.
- The 4-year median for Share-based Compensation is $100000.0 (2024), against an average of $154377.7.
- The widest annual swing landed in 2024, when Share-based Compensation slumped 85.71%; it then jumped 316.21% in 2025.
- Tracing NEUP's Share-based Compensation over 4 years: stood at $700000.0 in 2023, then slumped by 85.71% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025, then changed by 0.0% to $100000.0 in 2026.
- Per Business Quant, the three latest NEUP Share-based Compensation figures stand at $100000.0 (Q1 2026), $100000.0 (Q4 2025), and $111277.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 111,277.00 |
| Sep 30, 2025 | 111,277.00 |
| Jun 30, 2025 | 98,267.00 |
| Jun 30, 2025 | 98,267.00 |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 26,736.00 |
| Sep 30, 2024 | 26,736.00 |
| Jun 30, 2024 | 107,716.00 |
| Jun 30, 2024 | 107,716.00 |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 700,000.00 |
| Dec 31, 2023 | 700,000.00 |
| Sep 30, 2023 | 132,739.00 |
| Sep 30, 2023 | 132,739.00 |